Cell therapy (Tumor-infiltrating lymphocytes) · Kills target cells, directed at tumor cells · developed by Lyell Immunopharma
LYL845 is an autologous tumor infiltrating lymphocyte (TIL) therapy enhanced through epigenetic reprogramming. The expanded TILs are enriched for CD8-positive T-cells with diverse tumor-reactive clones and stem-like characteristics. It is being studied in melanoma, non-small cell lung cancer, and colorectal cancer.
Summary written with AI from the sources listed at the end of this page.
| Trial | Phase | Condition | Status | Sponsor |
|---|---|---|---|---|
| NCT05573035 | Phase 1 | Melanoma | Terminated | LYEL |
Trials of the companies BioRadar tracks, from ClinicalTrials.gov, most advanced phase first.
Colorectal CancerMelanomaNon-small Cell Lung Cancer
Updated Oct 3, 2026. Something wrong or missing? Report it on the LYEL page.
See LYEL's upcoming FDA decisions, trial readouts, cash runway and dilution risk, updated every day from SEC, FDA and ClinicalTrials.gov filings.
LYEL catalysts and pipeline →